Drug
GS 9674
GS 9674: highest development phase Phase 2, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| GS-9674 NCT02854605 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) |
Latest
No recent events.
Follow GS 9674 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.